Martin J. Cannon

Federal Grant PI High Impact

Researcher

University of Arkansas for Medical Sciences

faculty

44 h-index 157 pubs 5,866 cited

Research Areas

Cancer Immunotherapy and Biomarkers Pancreatic and Hepatic Oncology Research Virus-based gene therapy research Immune Response and Inflammation T-cell and B-cell Immunology Cancer Treatment and Pharmacology Microbial infections and disease research Health and Medical Research Impacts

Links

ORCID Lab Website Research Group UAMS TRI Profile

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

Martin J. Cannon's research focuses on the development and application of oncolytic viruses and immunotherapies for cancer treatment. His work investigates the potential of various viruses, including Myxoma virus and Morreton virus, as platforms for selectively targeting and destroying cancer cells. A significant portion of his research explores strategies to enhance the efficacy of these virotherapies, often in combination with other treatments like immune checkpoint blockade.

Cannon's published work includes studies on enhancing CD4 T cell-dependent antitumor immunity in ovarian cancer, the immune responses stimulated by modified Myxoma viruses in human monocytes and macrophages, and the characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers. He has also explored repurposing existing vaccines, such as the MMR vaccine, for cancer immunotherapy and investigated methods to improve resectability in pancreatic cancer through enhanced neoadjuvant virotherapy by targeting the tumor stroma.

His scholarly contributions are reflected in a high h-index of 44 and over 5,800 citations across 157 publications. Cannon has secured federal funding for his research, including an NIH/National Cancer Institute grant for studying mechanisms of Th17-DC immunotherapy for ovarian cancer and an NIH/NIH Office of the Director grant as Co-PI for research on platelets in radiation-induced immune dysregulation. He collaborates with researchers at the University of Arkansas for Medical Sciences and other institutions.

Metrics

h-index: 44
Publications: 157
Citations: 5,866

Selected Publications

Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models (2025) DOI
Abstract B022: Reprogramming Apoptotic Resistance in PDAC Through Synthetic Oncolytic Immunotherapy (2025) DOI
Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response (2025) DOI
A Replication-Defective Myxoma Virus Inducing Pro-Inflammatory Responses as Monotherapy and an Adjuvant to Chemo- and DC Immuno-Therapy for Ovarian Cancer (2025) DOI
Abstract 945: Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models (2025) DOI
Abstract 947: Engineering a synthetic oncolytic virus to overcome apoptotic resistance and induce immunogenic cell death in pancreatic ductal adenocarcinoma (2025) DOI
Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer (2024) DOI
Abstract 5004: Oncolytic Jurona-driven systemic and intratumoral immunotherapy combined with immune checkpoint blockade boost immune response and survival in hepatocellular carcinoma models (2024) DOI
Th17-inducing dendritic cell vaccines stimulate effective CD4 T cell-dependent antitumor immunity in ovarian cancer that overcomes resistance to immune checkpoint blockade (2023) DOI
Supplemental Figures 1-9 and Table S1 from Gastrointestinal Tract Dysbiosis Enhances Distal Tumor Progression through Suppression of Leukocyte Trafficking (2023) DOI
Supplemental Figures 1-9 and Table S1 from Gastrointestinal Tract Dysbiosis Enhances Distal Tumor Progression through Suppression of Leukocyte Trafficking (2023) DOI
Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy (2022) DOI
Myxoma virus lacking the host range determinant M062 stimulates cGAS-dependent type 1 interferon response and unique transcriptomic changes in human monocytes/macrophages (2022) DOI
Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers (2022) DOI
Abstract 3529: T-cell trafficking and extravasation is suppressed in distal tumors during gastrointestinal tract dysbiosis (2022) DOI